Matthew P Deek, Philip Sutera, Yuezhou Jing, Robert Gao, Emily Rothman, Heather Day, David Chang, Piet Dirix, Andrew J Armstrong, Bethany Campbell, Fernando Lopez Campos, Miguel Berenguer, Matthew Ramotar, Antonio Conde-Moreno, Alejandro Berlin, Davide Giovanni Bosetti, Niall Corcoran, Bridget Koontz, Carole Mercier, Shankar Siva, David Pryor, Piet Ost, Mai Anh Huynh, Stephanie Kroeze, Bradley Stish, Ana Kiess, Bruce Trock, Phuoc T Tran, Silke Gillessen, Christopher Sweeney
BACKGROUND: Metastasis-directed therapy (MDT) is increasingly being used in oligometastatic castration-sensitive prostate cancer (omCSPC). However, it is currently unclear how to optimally integrate MDT with the standard of care of systemic hormonal therapy. OBJECTIVE: To report long-term outcomes of MDT alone versus MDT and a defined course of androgen deprivation therapy (ADT) in omCSPC. DESIGN, SETTING, AND PARTICIPANTS: Here, a multicenter, international retrospective cohort of omCSPC as defined by conventional imaging was reported...
April 2, 2024: European Urology Oncology